Quantum BioPharma Advances Multiple Sclerosis Drug Toward Clinical Trials
TL;DR
Quantum BioPharma gains advantage by signing agreement for Lucid-MS IND application, positioning for Phase 2 clinical trial for multiple sclerosis treatment.
Quantum BioPharma partners with global CRO to submit Lucid-MS IND to FDA in Q4 2025, aiming to prevent demyelination in MS and neurodegenerative disorders.
Quantum BioPharma's Lucid-MS therapy could improve lives by halting myelin degradation, offering hope for better treatments in neurodegenerative diseases like MS.
Quantum BioPharma's innovative approach to neuroprotection with Lucid-MS shows promise in addressing the complex mechanisms of multiple sclerosis and other disorders.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. has taken a significant step toward advancing its multiple sclerosis treatment by signing an agreement with a global pharmaceutical contract research organization to prepare an Investigational New Drug (IND) application for its lead compound, Lucid-21-302.
The company plans to submit the IND to the FDA in the fourth quarter of 2025, which would potentially enable initiation of a Phase 2 clinical trial. Lucid-21-302 represents a novel approach to treating multiple sclerosis, functioning as a non-immunomodulatory neuroprotective therapy designed to prevent demyelination.
Preclinical studies have demonstrated the compound's potential to address a critical mechanism in neurodegenerative disorders. By targeting myelin degradation, Lucid-21-302 could offer a new therapeutic strategy for patients with multiple sclerosis and potentially other neurological conditions.
The development is significant because current multiple sclerosis treatments often focus on managing symptoms or modulating the immune system. In contrast, Lucid-21-302 aims to directly protect neural structures, potentially offering a more fundamental approach to treating the disease.
Quantum BioPharma's strategic move highlights the ongoing innovation in neurodegenerative disease research and represents a potential breakthrough in multiple sclerosis treatment methodology.
Curated from InvestorBrandNetwork (IBN)
